Orange Book product · Generic (ANDA)
NEVIRAPINE
NEVIRAPINE
At a glance
Aug 03, 2017
Approved
Generic (ANDA)
Application
AA
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Aug 03, 2017
9 yr ago
Today
Pharmaceutical detail
Active ingredient
NEVIRAPINE
Strength
50MG/5ML
Dosage form
SUSPENSION
Route
ORAL
TE code
AA
Application
ANDA 207684
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of NEVIRAPINE
- 2012VIRAMUNE XRBrand (NDA)
NDA 201152 · BOEHRINGER INGELHEIM
- 1998VIRAMUNEBrand (NDA)
NDA 020933 · BOEHRINGER INGELHEIM
- 1996VIRAMUNEBrand (NDA)
NDA 020636 · BOEHRINGER INGELHEIM
- 2019NEVIRAPINEGeneric (ANDA)
ANDA 090688 · MACLEODS PHARMS LTD
- 2017NEVIRAPINEGeneric (ANDA)
ANDA 206879 · MACLEODS PHARMS LTD
- 2017NEVIRAPINEGeneric (ANDA)
ANDA 207467 · TECH ORGANIZED
- 2017NEVIRAPINEGeneric (ANDA)
ANDA 207698 · AUROBINDO PHARMA
- 2016NEVIRAPINEGeneric (ANDA)
ANDA 208616 · AUROBINDO PHARMA
- 2015NEVIRAPINEGeneric (ANDA)
ANDA 204621 · ALVOGEN
- 2015NEVIRAPINEGeneric (ANDA)
ANDA 206271 · PHARMOBEDIENT
- 2015NEVIRAPINEGeneric (ANDA)
ANDA 206448 · CIPLA
- 2014NEVIRAPINEGeneric (ANDA)
ANDA 205651 · MYLAN
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
